1 / 52

Four Key Issues for Court-Directed Drug Testing

Four Key Issues for Court-Directed Drug Testing. By: Paul L. Cary Toxicology Laboratory University of Missouri. The law is not black and white and neither is science. “. . there is a substantial gap between the questions that the legal community would like

Download Presentation

Four Key Issues for Court-Directed Drug Testing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Four Key Issues for Court-Directed Drug Testing By: Paul L. Cary Toxicology Laboratory University of Missouri

  2. The law is not black and white and neither is science. “. . there is a substantial gap between the questions that the legal community would like to have answered by drug testing and the answers that the scientific community is able to provide. The real danger lies in the legal community’s failure to “mind the gap” by drawing unwarranted inferences from drug testing results.”

  3. Four Key Issues • interpreting urine drug testing results • eliminating the use of urine drug levels in court proceedings • establishing a pragmatic cannabinoid detection window • monitoring alcohol abstinence using EtG determinations

  4. Interpretation ofUrine Drug Test Results

  5. Negative or None Detected Results • indicates that no drugs or breakdown products (metabolites), tested for, were detected in the sample tested • no such thing as “zero” tolerance or “drug free” • negative does not mean NO drugs present

  6. Negative/None Detected Interpretation • client is not using a drug that can be detected by the test Other possible explanations • client not using enough drug • client’s drug use is too infrequent • collection too long after drug use • urine is tampered • test being used not sensitive enough • client using drug not on testing list

  7. Negative/None Detected Interpretation • no need to second-guess every “negative” result • not suggesting withholding positive reinforcement & rewards for positive behaviors • drug testing is a monitoring tool • assess none detected drug testing results in the context of your client’s overall program compliance (or non-compliance) and their life’s skills success (or lack thereof)

  8. Positive Test Result Interpretation • indicates that drug(s) or breakdown products (metabolites), tested for, were detected in the sample tested • drug presence is above the “cutoff” level • greatest confidence achieved with confirmation • ALWAYS confirm positive results in original sample

  9. What is a “cutoff” level ? • a drug concentration, administratively established for a drug test that allows the test to distinguish between negative and positive sample - “threshold” • cutoffs are not designed to frustrate CJ professionals • cutoffs provide important safeguards: • scientific purposes (detection accuracy) • legal protections (evidentiary admissibility) • measured in ng/mL = ppb

  10. Typical Cutoff Levels screening & confirmation • amphetamines * 1000 ng/mL 500 ng/mL • benzodiazepines 300 ng/mL variable • cannabinoids * 20 & 50 ng/mL 15 ng/mL • cocaine (crack)* 300 ng/mL 150 ng/mL • opiates (heroin) * 300/2000 ng/mL variable • phencyclidine (PCP) * 25 ng/mL 25 ng/mL • alcohol 20 mg/dL 10 mg/dL • * SAMHSA (formerly NIDA) drugs

  11. No such thing as “zero tolerance” testing • drug tests not capable of testing to “0” ng/mL • each drug & each drug test has a limit of detection • drug courts urged to utilize “standardized” cutoffs • potential hazards of a “zero-tolerance” approach (use of non-traditional cutoffs) • testing accuracy (increase in false-positives) • court’s justification for abnormally low cutoffs • can/will your laboratory “defend” low cutoffs • increased challenges/scrutiny to positive results • lowered cutoffs may include “inadvertent” exposures

  12. Isn’t any amount of drug in a client’s system a violation? • punishment model vs. therapeutic model • drug testing results (which form the foundation for incentives & sanctions) need to be scientifically accurate & legally defensible • protection of client rights & the court

  13. Exceptional (lowered) cutoffs in an effort to “catch” covert client drug use: • provides only a marginal increase in drug detection • opens your court to increased scrutiny associated with potential false positives and resulting inappropriate sanctions • it’s all about credibility • it’s all about confidence

  14. The Issue of UrineDrug Concentrations

  15. Drug Tests are Qualitative • screening/monitoring drug tests are designed to determine the presence or absence of drugs - NOT their concentration • drug tests are NOT quantitative

  16. Drug concentrations or levels associated with urine testing are, for the most part, USELESS ! • cocaine metabolite 517 ng/mL • opiates negative • cannabinoids negative • amphetamines negative

  17. The Twins 200 mg Wonderbarb @ 8:00 AM Collect urine 8:00 PM 12 hours later A B

  18. The Twins - urine drug test results A B Wonderbarb = 638 ng/mL Wonderbarb = 3172 ng/mL

  19. The Twins - urine drug test results physiological make up exact amount drug consumed exact time of ingestion exact time between drug exposure and urine collection AND YET . . . . . A B

  20. The Twins - urine drug test results Twin B’s urine drug level is5 times higher than Twin A A B Wonderbarb = 638 ng/mL Wonderbarb = 3172 ng/mL

  21. Are any of the following questions being asked in your court? • How positive is he/she? • Are his/her levels increasing or decreasing? • Is that a high level? • Is he/she almost negative? • Is this level from new drug use or continued elimination from prior usage? • What is his/her baseline THC level? • Does that level indicate relapse? • Why is his/her level not going down? (or up?)

  22. THE ISSUE Urine drug concentrations are of little or no interpretative value. The utilization of urine drug test levels by drug courts generally produces interpretations that are inappropriate, factually unsupportable and without a scientific foundation. Worst of all for the court system, these urine drug level interpretations have no forensic merit.

  23. Where do urine drug levels come from? lower drug level higher drug level 20 ng/mL NEGATIVE RESULT POSITIVE RESULT screening drug testing cutoff

  24. Scientific Rationale • Technical Issues • testing not linear • tests measure total drug concentrations • Physiological • variability of urine output • differential elimination of drug components

  25. “Expected Values: When the test is used as a qualitative assay, the amount of drugs and metabolites detected by the assay in any given specimen cannot be estimated. The assay results distinguish between positive and negative specimens only.”

  26. 432 indicates he going up, right? THIS ? is 22 above the cutoff? does 219 mean new use? 307 – well she’s almost negative, correct? 639 is really high for THC, isn’t it? I think 1200 is a new record, isn’t it? 115 is down from yesterday, probably continued elimination? 515 is much higher than last week, right? don’t we need to consider relapse at 57?

  27. OR THIS ? Negative or Positive

  28. Advantages of Eliminating Drug Levels • court decisions have a strong scientific basis & forensically sound • no longer attempt to interpret data that is not interpretable • greater confidence in decision making process • removes ambiguity associated with manipulating numbers that few in drug court are trained to do • adds additional fairness/equity in sanctions & rewards process

  29. Final Thought: However well-intentioned, the use of urine drug testing levels cannot be supported by the science and represents an adjudication practice that is not forensically defensible. An unambiguous and equitable evidentiary foundation that will pass both scientific and legal scrutiny is crucial to the continued success of drug courts (criminal justice).

  30. The Cannabinoid Detection Window

  31. Cannabinoid Detection in Urine • Conventional wisdom has led to the common assumption that cannabinoids will remain detectable in urine for 30 days or longer following the use of marijuana. • RESULT: • delay of therapeutic intervention • hindered timely use of judicial sanctioning • fostered denial of marijuana usage by clients

  32. Perpetuating 30-Plus Day Assumption • Substance abuse treatment literature that proclaims, “some parts of the body still retain THC even after a couple of months”. • Drug abuse information targeted toward teens “Traces of THC can be detected by standard urine and blood tests for about 2 days up to 11 weeks”. • Health information websites that provide the following guidance; “At the confirmation level of 15 ng/ml, the frequent user will be positive for perhaps as long as 15 weeks.” • And, last but not least Dr. Drew Pinsky (a.k.a. Dr. Drew) who has been the co-host on the popular call-in radio show "Loveline" for 17 years who states; “Pot stays in your body, stored in fat tissues, potentially your whole life.”

  33. Cannabinoids - Recent/Relevant Research • 30+ day detection window often exaggerates duration of detection window • reasonable & pragmatic court guidance • detection time: at 50 ng/mL cutoff • up to 3 days for single event/occasional use • up to 10 days for heavy chronic use • detection time: at 20 ng/mL cutoff • up to 7 days for single event/occasional use • up to 21 days for heavy chronic use

  34. Addressing Imperatives for Cannabinoids • acknowledge research reporting prolonged THC elimination • establish a reasonable and pragmatic detection window guidance for the vast majority of case adjudications • sound judicial practice requires that court decisions be based upon case-specific information • in unconventional situations that confound the court, qualified toxicological assistance should be sought

  35. Recent Cannabinoid Use versus Non-recent use (double sanction issue): • How do drug courts discriminate between new drug exposure and continued elimination from previous (chronic) use ? • an issue only in first phase of program • only drug that poses concern is cannabinoids • “two negative test” rule – two back-to-back negative drug tests post clean out

  36. Drug Court’s Competing Imperatives • the need for rapid therapeutic intervention (sanctioning designed to produce behavioral change) • the need to ensure that the evidentiary standards, crafted to protect client rights, are maintained

  37. Ethyl Glucuronide (EtG) – New Strategy for Monitoring Alcohol Abstinence

  38. Alcohol is the most commonly abused substance by drug court clients and the most difficult substance to detect in abstinence monitoring.

  39. Ethyl Glucuronide

  40. Advantages of Ethyl Glucuronide • unique biological marker of alcohol use (no false positives) • direct marker indicating recent use • longer detection window than alcohol • stable in stored specimens (non-volatile) • is not formed by fermentation • is not detected in the urine of abstinent subjects

  41. Urine EtG Concentrations Following Alcohol Consumption: • one 3.2% beer > 3800 ng/mL @ 4 hours detection up to 24 hours (alcohol - 90 minutes) • three 3.2% beers detection up to 48 hours (alcohol - 3.5 hours)

  42. Disadvantages of Ethyl Glucuronide • testing available at relatively few laboratories • testing somewhat costly ($25.00 price point) • introduction of numerous testing approaches besides LC/MS/MS • most significant concern – casual, inadvertent, environmental alcohol exposure causing positive results

  43. On September 25, 2006 everything changed!

  44. SAMHSA CSAT Advisory (9-25-06) “Currently, the use of an EtG test in determining abstinence lacks sufficient proven specificity for use as primary or sole evidence that an individual prohibited from drinking, in a criminal justice or a regulatory compliance context, has truly been drinking. Legal or disciplinary action based solely on a positive EtG, is inappropriate and scientifically unsupportable at this time. These tests should currently be considered as potential valuable clinical tools, but their use in forensic settings is premature.”

  45. Sources of “Incidental” Alcohol Exposure • medications (Nyquil) • mouthwashes (Listermint & Cepacol) • tincture of gingko biloba (herbal - memory) • foods containing alcohol (such as vanilla extract, baked Alaska, cherries jubilee, etc.) • “non-alcoholic” beers (O’Doul’s) • colognes & body sprays • insecticides (DEET) • alcohol-based hand sanitizers (Purell)

  46. What prompted SAMHSA Advisory ? • the science of EtG testing - ourcapability to employ highly sensitive testing procedures to detect recent ethyl alcohol exposure - has outpaced ourability to appropriately interpret the test results in a forensically defensible manner • consumption vs unintended exposure • CSAT (National Advisory Council) concluded that there is inadequate research data about the populations being tested

  47. Positive EtG Result (500 ng/mL): • a result reported as EtG positive in excess of the 500 ng/mL cutoff is consistent with the recent ingestion of alcohol-containing products (1-2 days prior to specimen collection) by a monitored client • studies examining “incidental” exposure widely conclude that results in excess of the 500 ng/mL cutoff are not associated with inadvertent or environment ethanol sources

  48. Current State of EtG Testing • my biggest concern is that this advisory will likely render ANY EtG result as legally inadmissible (for sanctioning purposes) • already seen large decrease in EtG testing nationally • EtG still valuable for therapeutic intervention

  49. Options for Client Sanctioning • positive urine EtG - cutoff of at least 500 ng/mL combined with: • a client admission of use/replase • identification of behavioral indicators • alcohol-related arrest or incident • alcohol-related job action • client seen in bar/tavern • a violation of EtG-specific contract

More Related